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Abstract 
Background: Tenofovir (TDF) based regimen was reported to have better immunological outcomes. Unfortunately, 
there is limited information regarding the immunologic outcome associated with this regimen in Ethiopia, as its rou-
tine utilization in this setting begun since 2013.
Methods: A 2 years retrospective cohort study was conducted at Jimma University Specialized Hospital, 346 km 
Southwest of Addis Ababa, Ethiopia. A total of 280 patients’ data from September 2012 to July 2014 was extracted 
from records from February 10, 2015 to March 10, 2015. Records were selected using a simple random sampling tech-
nique. Data on socio-demographic, clinical and drug related variables were collected; entered into EpiData 3.1 and 
analyzed by STATA 13.1. Mixed effect linear regression was performed to assess difference in CD4+ change between 
groups adjusting for baseline characteristics. The change in predicted CD4 count attributed to each regimen was also 
assessed by marginal analysis. P < 0.05 for slopes of the random effect linear regression was used as indicators for 
presence of association.
Results: The mean (SD) duration of cohort follow up was 714.2 (69.6) and 708.8 (78.9) days (P = 0.753) for TDF and 
AZT groups respectively. The minimum follow up duration was 7.4 and 8.9 months for TDF and AZT groups respec-
tively. Most of TDF (93.6%) and AZT (91.4%) groups completed their follow up, 5 (3.6%) TDF and 6 (4.3%) AZT groups 
died and 4 (2.9%) TDF and 6 (4.3%) AZT groups were lost for follow-up (P = 0.769). There was statistically significant 
difference in immunologic recovery between the groups (B = +34.08, 95% CI [7.8, 60.35], P = 0.027) over time. The 
predicted CD4+ count for TDF/3TC/EFV was (B = +347.65 cells/mm3, P < 0.001) whereas that of AZT/3TC/EFV was 
(B = +281.54 cells/mm3, P < 0.001).
Conclusions: TDF based regimens have shown more efficacy compared to AZT based regimens though AZT based 
regimens are more affordable in low income countries like Ethiopia. However, we recommend further study with 
quality design to assess the prevalence of sub-optimal CD4+ response (net CD4 gain <50 cells/µl/6 month) in this 
set-up among TDF users.
Keywords: Immunological outcomes, Tenofovir regimen, Zidovudine regimen, Ethiopia
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Around 1980s, Acquired immunodeficiency syndrome 
(AIDS) was globally emerged as a major public health 
threat. The reaction against it has led to unprecedented 
attention and commitment from the international com-
munity to improve access to human immune virus(HIV) 
care, antiretroviral treatment (ART) and prevention 
[1, 2]. The introduction of potent ART has dramatically 
reduced HIV/AIDS associated crisis—reduced rates 
of mortality and morbidity, improved quality of life, 
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revitalized communities and transformed perceptions on 
the disease from a plague to a manageable chronic illness 
[3–6].
Currently, there are more than 20 ARV compounds 
approved for use in United States (US) and Europe. 
Multiple adult HIV treatment guidelines recommend 
the nucleos(t)ide reverse transcriptase inhibitors; AZT 
or TDF based regimens and most are in favour of TDF 
based regimens as the safer regimen for patients with no 
contraindication due to its proven effectiveness, favour-
able toxicity profile, and demonstrated regimen durabil-
ity [1, 7–9].
Safe and efficacious ART regimens improve patient 
care through rapidly restoring the immune cells, promot-
ing adherence and alleviating the hazards of mortality [1, 
10, 11]. TDF is one of the ART drugs that come to be rou-
tinely utilized in Ethiopia since the past 2 years. For this 
drug, the recent WHO report indicated that data on the 
risk of major clinical events such as mortality, renal fail-
ure and, bone fractures were limited, and particularly for 
our setups there is no immunologic finding as well [11].
Studies from developed regions showed that there were 
18.0 and 18.8% immunologic failures in the EFV/FTC/
TDF and EFV/3TC/AZT arms, respectively. There were 
no significant differences in the risk of HIV-1 disease 
progression or death [12]. In other findings, TDF based 
regimens has demonstrated a better immunologic out-
come only when combined with Efavirenz as compared 
to AZT based preparations [3, 13, 14]. In contrary, a find-
ing from south Africa concludes that, in population of 
HIV patients on treatment in resource-limited settings 
AZT-containing regimens appear to show a slightly pro-
tective than TDF-based regimens [15]. Despite, this evi-
dence variation, its immunologic benefits unknown in an 
Ethiopian setting where patients generally present late, 
have high rates of TB and other infectious conditions 
[16]. Hence further investigation, particularly in health 
setups of the current setting‚ was warranted. Therefore, 
this study was aimed to provide additional information 
by making a head to head comparison of the two regi-
mens in terms of immunologic benefits and associated 




The study was conducted at Jimma University specialized 
Hospital which is located in Jimma town; Jimma Zone, 
346 km Southwest of Addis Ababa, Ethiopia. The hospital 
has separate ART clinic with about 7486 clients. The ART 
clinic provides HIV and TB treatment and care. Patient 
data from September 2012 to July 2014 was extracted 
from records from February 10, 2015 to March 10, 2015.
Study design and population
A retrospective hospital based cohort study was con-
ducted on adult patients who were on TDF and AZT 
based regimens and fulfilled inclusion criteria. The study 
was conducted by dividing the total sample into two 
groups: TDF and AZT groups.
Inclusion and exclusion criteria
We included patients who were older than 14 years, have 
at least 6 months follow-up, whose records were legible 
and complete, and who have at least baseline and sixth 
month CD4 count. We excluded pregnant women from 
the study because there is significant pharmacokinetic 
change that is enough to impact the treatment outcome 
in this group of population. Those whose regimen was 
changed were also excluded from the study.
Sample size and sampling techniques
Sample size determination was guided by the number of 
patients on TDF/3TC/NVP where only 70 patients ful-
filled the inclusion criteria. Patients from other regimens 
were selected based on the size of this group to satisfy 1:1 
ratio of AZT to TDF group. Therefore, frequency match-
ing was used to select a total of 280 subjects (140 TDF 
group and 140 AZT group). Records were selected by 
simple random sampling technique using computer gen-
erated random numbers.
Data collection
Data on demographic, clinical, laboratory, drug admin-
istered, comorbidities and adherence were collected 
by record review using English version checklist which 
was prepared after reviewing different relevant litera-
tures. Baseline body mass-index of the subjects was cal-
culated after collection of baseline height and weight of 
the patient from patients chart. Data from antiretroviral 
drugs sheet and patient information sheet were collected 
by pharmacists, while nurses collected data from ART 
intake and follow up forms.
Data processing and analysis
Data were double entered into Epi-Data 3.1 and exported 
to STATA 13.1 for cleaning and analysis. Descriptive 
analyses were performed and results were presented 
by text, tables and charts. Bi-variate and multivariable 
mixed effect linear regression for repeated measurements 
were performed to assess adjusted effect of the ART regi-
men and identify additional predictors of CD4 recovery. 
Coefficient of mean CD4 count with 95% confidence 
intervals was used as measure of strength of association 
and P < 0.05 was considered to declare a statistical signif-
icance. Marginal analysis was also conducted to see the 
difference among specific regimen category.
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Results
A total of 1034 patients were on antiretroviral therapy 
(ART) for at least 6 months during the study period. Nine 
hundred eighty six had complete CD4+ count at 6 month 
of treatment. Fourteen records were used for pre-test, 22 
and 110 records were excluded because of pregnancy and 
regimen change respectively. Only 70 patients remained 
on TDF/3TC/NVP and this governed the sample selec-
tion (Fig. 1).
The cohort was followed for 2 years. The overall time the 
cohort was at risk was 539.39 years. The cohort contributed 
to a total of 2.74/100 and 2.72/100 person-years of follow-
up for TDF and AZT groups respectively. The mean (SD) 
duration of follow up was 714.2 (69.6) and 708.8 (78.9) days 
(P = 0.753) for TDF and AZT groups respectively. The min-
imum follow up duration was 7.4 and 8.9 months for TDF 
and AZT groups respectively. Most of TDF (93.6%) and 
AZT (91.4%) groups completed their follow up, 5 (3.6%) 
TDF and 6 (4.3%) AZT groups died and 4 (2.9%) TDF and 6 
(4.3%) AZT groups were lost for follow-up (P = 0.769).
Baseline socio‑demographic and behavioural 
characteristics
Majority of TDF (64.3%) and AZT (66.4%) groups were 
females. Majority of TDF (77.1%) and AZT (85.9%) 
groups were in the age group 25–45 years with mean (SD) 
of 32.3 (7.4) and 32.3 (9.2) years respectively. Majority of 
TDF (62.9%) and AZT (73.6%) groups had BMI ≥ 18 kg/
* excluded patients
On ART at least for 6 
months   (n= 1034)






*adherence problem (n=43)                   
AZT/3TC/EFV (n=105)
*adherence problem (n=19)
AZT arm (n= 352)
*pregnant (n=12)
TDF/3TC/NVP (n=92)











Had CD4 count at 6 month (n=986)
Enrolment
*Used for pre-test 
(n=14)
Fig. 1 Sample recruitment diagram from cohort of patients on ART for at least 6 months at JUSH, September, 2012 to July, 2014
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m2 with mean (SD) of 19.7 (3.4) and 20.4 (3.0) respec-
tively. Larger proportion of TDF (48.6%) and AZT 
(41.5%) groups were employed. Majority of TDF (69.3% 
and AZT (78.5%) groups were urban. Concerning alcohol 
use, most of TDF (80.7%) and AZT (72.9%) groups had 
history of alcohol use. Regarding between groups com-
parison of distribution of baseline socio-demographic 
and behavioural characteristics of patients, there was 
statistically significant difference between groups only in 
terms of religion (Table 1).
Baseline clinical characteristics
Majority of TDF (65.7%) and AZT (53.9%) groups 
had baseline CD4+  count <200 cells/mm3 with mean 
(SD) of 164.64 (83.36) and 175.21 (89.14) respectively. 
There was statistically significant difference between 
groups in terms of baseline CD4 count. Leading per-
centage (33.6%) both TDF and AZT groups were in 
WHO clinical stage III and II respectively. Most of 
TDF (78.6%) and majority of AZT (56.4%) groups 
had working functional status and there was statisti-
cally significant difference between groups. Twenty 
(15.3%) and 17 (12.1%) of patients were treated for 
TB from TDF and AZT groups respectively. CPT 
was prescribed for most of (87.9%) and nearly all of 
(92.14%) patients in TDF and AZT groups respec-
tively, whereas INH was prescribed for only 26.4 and 
21.5% of patients in TDF and AZT groups respectively 
(Table 2).
Immunologic outcome (CD4+ change)
The mean change in CD4+ over study period is shown by 
Fig.  2. The overall mean (SD) CD4+  has shown greater 
improvement among TDF [321.7 (164.8)] than AZT 
group [299.4 (126.1)]. If each regimen is considered sepa-
rately, the maximum and minimum mean CD4+  count 
gain at any given time was attained by TDF/3TC/EFV and 
AZT/3TC/EFV groups respectively (Fig. 2).
At 6  month, the overall proportion of sub-opti-
mal CD4+  response (net CD4+  gain  <50  cells/µl) 
was 23.95% (30% TDF/EFV, 28.3% AZT/EFV, and 
23.8% TDF/NVP). Earlier at the initiation of ART, the 
CD4+ count showed a linear trend but it becomes more 
flat after 18th month with a very minimal gain irrespec-
tive of the regimen.
Predictors of CD4+ change
Considering consecutive CD4+  count as an outcome 
variable, multilevel mixed effect linear regression was 
performed (Table  3). The slope of random-effect mul-
tiple linear regression was used to interpret the over-
time change in CD4+  count attributed to the predictor 
variables.
Accordingly, the average gain in CD4+ count achieved 
at every visit among the cohort was 38 cells/mm3 
(B  =  38.18, 95% CI [33.11,43.24], P  <  0.001) with the 
conditional correlation coefficient of 64.9%, i.e. 64.9% 
of the variability in CD4+ count between two visits was 
explained by unobserved patient specific factors. Among 
these, 38.99% of the variation in CD4+  change was 
Table 1 Socio-demographic and  behavioural character-
istics for  cohort of  patients on  ART for  a least 6 months 
at JUSH, September 2012 to July 2014











 Male 50 (35.7) 47 (33.6) 0.706
 Female 90 (64.3) 93 (66.4)
Age
 <25 27 (19.3) 32 (25.9) 0.276
 25–45 108 (77.1) 98 (85.9)
 >45 5 (3.6) 10 (7.2)
 Mean (SD) 32.3 (7.4) 32.3 (9.2) 0.977**
BMI
 <18.5 52 (37.1) 37 (26.4) 0.130
 ≥18.5 88 (62.9) 93 (73.6)
 Mean (SD) 19.7 (3.4) 20.4 (3.0) 0.062**
Educational level
 Illiterate 22 (15.8) 30 (21.4)
 Primary 48 (34.2) 58 (41.4) 0.089
 Post-primary 70 (50) 52 (37.2)
Residence
 Urban 97 (69.3) 110 (78.5) 0.077
 Rural 43 (30.7) 30 (21.5)
Occupation
 Employed 68 (48.6) 58 (41.5)
 Unemployed 46 (22.8) 55 (39.2) 0.446
 Housewife 26 (18.6) 27 (19.3)
Religion
 Orthodox 59 (42.1) 80 (57.1)
 Muslim 45 (32.1) 42 (30) 0.010*
 Others 36 (25.8) 18 (12.9)
Marital status
 Married 76 (54.3) 77 (55.0)
 Single 23 (16.5) 29 (20.7) 0.207
 Divorced 33 (23.5) 21 (15.1)
 Widowed 8 (5.7) 13 (9.2)
Alcohol use
 Yes 113 (80.7) 102 (72.9)
 No 27 (19.3) 38 (27.1) 0.120
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explained by differences in the regimens where as 25.34% 
of the variation is attributed to other regression variables 
(P < 0.001), showing an important heterogeneity between 
patient groups.
In the overall analysis, keeping other factors constant, 
older age was found to be one of the negative predictors of 
CD4+ count change. So younger patients (age <25 years) 
were found to have +66 gain in CD4+  count every 6 
months as compared to those aged ≥45 years (B = −66.19 
95% CI [−126.68, −5.70], P = 0.032).
Among the predictor variables, female sex was strongly 
associated with progressive CD4+  count gain at each 
visit. So, females had +39 CD4+  cells advantage over 
time (B  =  33.86, 95% CI [33.11, 43.24], P  =  0.013) as 
compared to males. Patients with BMI ≥ 18.5 kg/m2 had 
a significantly higher CD4+ change (+32 cell/mm3) over 
time than those who had BMI  <  18.5  kg/m2 (B = −32, 
95% CI [−60.16, −4.27], P = 0.011).
Baseline CD4+  count was also another independent 
predictor for CD4+ advantage over time (β = 0.879, 95% 
CI [0.70, 1.06], P < 0.001). More importantly, patients in 
TDF group had a significant CD4+  count gain per visit 
compared with their AZT counterparts (B = 34.08, 95% 
CI [7.80, 60.35], P = 0.027).
In this study, other baseline patient factors such as 
WHO clinical stage, TB treatment, educational status, 
place of residence, religion, occupational status, marital 
status, alcoholic use and prophylaxis had no significant 
association with CD4+ change.
Marginal analysis
To predict the expected change in CD4+  count in both 
groups at the end of treatment period, post-estimation 
marginal analysis was conducted.
In TDF group, the predicted mean CD4+  count 
changes were 347.65 and 295.73  cells/mm3 for patients 
treated with TDF/3TC/EFV and TDF/3TC/NVP respec-
tively. In AZT group, the predicted mean CD4+  count 
changes were 319.11 and 281.54  cells/mm3 for patients 
treated with AZT/3TC/NVP and AZT/3TC/EFV respec-
tively. These figures were exactly the expected increase 
in CD4+ count associated with each regimen and has a 
crucial clinical implication in guiding clinicians to choose 
which regimen to initiate on as the role of good immu-
nologic recovery in treatment of HIV infection is multi-
dimensional. So, this section of analysis (Table 4) clearly 
showed that the overall outcome was better in TDF than 
AZT group.
Discussion
Analysis of every 6 month mean CD4+ gain showed that 
the maximum gain in mean CD4+  count was attained 
by TDF/3TC/EFV followed by AZT/3TC/NVP and 
TDF/3TC/EFV at any given time in the course of therapy. 
AZT/3TC/EFV had the least immunologic recovery over 
the entire treatment course. The CD4+  count showed 
a linear trend but became more flat after 18th month 
with a very minimal gain irrespective of the regimen. 
The overall prevalence of sub-optimal CD4+  response 
was found to be 67 (23.95%). At first 6 months, major-
ity of sub-optimal immunologic responders belonged 
Table 2 Baseline and  on follow up  clinical characteristics 
for cohort of patients on ART for a least 6 months at JUSH, 
September 2012 to July 2014




TDF group no (%) AZT group no (%) P value
Baseline CD4+ count
 <200 92 (65.7) 74 (53.9) 0.029*
 ≥200 48 (34.3) 66 (47.1)
 Mean (SD) 164.64 (83.36) 175.21 (89.14) 0.307**
Baseline WHO clinical stage
 I 32 (22.9) 36 (25.7)
 II 46 (32.9) 47 (33.6) 0.928
 III 47 (33.6) 43 (30.7)
 IV 15 (10.6) 14 (10)
Baseline functional status
 W 110 (78.6) 79 (56.4)
 A 24 (17.1) 56 (40.0) 0.000*
 B 6 (4.3) 5 (3.6)
TB Treatment
 No 120 (84.7) 113 (87.9) 0.773
 Yes 20 (15.3) 17 (12.1)
Prophylaxis
 CPT+ INH 37 (26.4) 30 (21.5)
 CPT alone 86 (61.4) 99 (70.7) 0.231












































AZT/NVPᵅ AZT/EFVᵇ TDF/NVPᶜ TDF/ᵈEFV
Fig. 2 Average gain in CD4+ count taken every 6 month for a cohort 
of patients on ART for at least 6 months at JUSH, September, 2012 to 
July, 2014. Missing values per each regimen at 12, 18 and 24 months 
respectively:  a(2, 7, 11); b(11, 3, 2); c(7, 1, 9); d(5, 12, 4)
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Table 3 Random-effect linear regression analysis of trend of CD4+ count (slope, cells/mm3/6 month) at JUSH, September 
2012 to July 2014
Variable Unadjusted Adjusted
B [95% CI] P value B [95% CI] P value
Sex
 Male 0 0
 Female 52.373 [21.22, 84.24] 0.001 33.86 [33.11, 43.24] 0.013
Age
 <25 0 0
 25–45 −53.15 [−90.03, −16.27] 0.005 −27.32 [−59.3, 4.66] 0.094
 >45 −120.87 [−191.24, −50.49] 0.001 −66.19 [−126.68, −5.70] 0.032
BMI
 <18.5 −48.08 [−80.42, −15.74] 0.004 −32.77 [−60.16, −4.27] 0.011
 ≥18.5 0 0
Educ. level
 Illiterate −0.5 [−42.86, 41.86] 0.982




 Rural −12.35 [−47.18, 22.54] 0.488
Occupation
 Employed 0 0.936 0 0.796
 Unemployed −1.40 [−32.23, 32.44] 0.015 3.96 [−26.04, 33.95] 0.293
 House wife 51.50 [10.2, 92.80] 21.35 [−18.42, 61.12]
Marital status
 Single 30.25 [−11.18, 71.68] 0.152 40.45 [0.52, 80.37] 0.069
 Married 0 0.525 0
 Divorced 13.06 [−27.17, 53.29] 0.513 6.42 [−32.27, 45.11] 0.745
 Widowed −19.89 [−79.56, 39.77] −2.33 [−55.27, 50.6] 0.931
Religion
 Orthodox 0 0
 Muslim 22.91 [−12.00, 57.83] 0.198 20.83 [−8.86, 50.53] 0.166
 Other 0.21 [−40.70, 41.13] 0.992 −12.09 [−46.89, 22.71] 0.496
Alcohol
 Yes −26.1 [−62.15, 9.94] 0.156 8.48 [−22.88, 39.83] 0.596
 No 0 0
ART regimen
 TDF 11.58 [−18.98, 42.15] 0.458 34.08 [7.80, 60.35] 0.027
 AZT 0 0
Baseline CD4+ count 0.97 [0.80, 1.15] 0.000 0.879 [0.70, 1.06] 0.000
WHO stage
 I 0
 II −16.76 [−57.59, 24.06] 0.421
 III −23.17 [−64.32, 17.97] 0.270
 IV −29.27 [−86.35, 27.81] 0.315
TB (treatment)
 No 0 0
 Yes −48.18 [−85.37, 5.00] 0.081 −20.74 [−59.05, 17.57] 0.289
Prophylaxis
 CPT+ INH 0 0
 CPT alone −29.40 [−65.65, 6.85] 0.112 −10.34 [−40.57, 19.88] 0.502
 Neither −40.89 [−97.93, 16.16] 0.160 −22.3 [−70.33, 25.73] 0.363
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to TDF/3TC/EFV (30%) and lowest proportion of sub-
optimal immunologic responder was observed among 
AZT/3TC/EFV (17.9%).
Our finding of mean CD4+ recovery was in agreement 
with a randomized multi-centre open-label study by Gal-
lant et al. [9], where a maximum immunologic response 
was achieved by TDF/3TC/EFV (270 cells/mm3) followed 
by AZT/3TC/EFV (237 cells/mm3) at 96 weeks. Another 
finding from Nigeria indicated that TDF/3TC/NVP is 
much more inferior (208  cells/mm3) to AZT/3TC/NVP 
(221.1 cells/mm3) at 12 months of therapy [17]. The dif-
ference in the outcome when TDF/3TC is combined with 
EFV and NVP may be due to negative pharmacokinetic 
or pharmacodynamics interaction between this NRTI 
backbone and NVP. The finding from the marginal analy-
sis also indicated that change in mean CD4+ count is sig-
nificantly higher in TDF based EFV regimen.
The bi-phasic CD4+ count response shown in our find-
ing was also reported by other findings [18, 19] as a rapid 
increase of memory CD4+  cells (a high CD4+  count 
slope) in the first several months after treatment initia-
tion succeeded by a slow increase in naive CD4+  cells 
(smaller slope compared to the initial several months). 
The linear trend in CD4+  increment at early phase of 
of therapy became flat with minimal CD4+  gain latter 
after 18th month of treatment irrespective of the regimen 
used. So “when will target CD4+  count (500–800 cells/
mm3) be attained after initiation of ART?” is the question 
to be addressed by further study.
Immunologic response after 6 months of ART indicates 
a favourable clinical outcome in HIV-1 infected patients 
regardless of virologic response [20]. Several studies 
has reported that as many as 8–40% of patients on ART 
do not show a significant increase in CD4+  cell count 
despite viral suppression [18, 21, 22]. Our finding, in gen-
eral, is almost consistent with these studies.
To these days, studies are unable to justify the impact 
of ART regimen on sub-optimal immunologic recovery. 
So, it is not surprising that most of these patients in this 
study were from TDF based regimens. As the recovery 
of the CD4+ T-cell count is hindered by several patient 
and viral factors, including: residual viral replication, 
impaired thymic function, advanced age, enhanced T-cell 
activation and apoptosis, genetic variations, baseline 
anaemia and poor adherence [18, 21, 23, 24], our finding 
might not quest the efficacy of TDF based regimens in 
resource limited settings, even though it needs a further 
workup with adequately powered and methodological 
high quality study.
Study by Mauro et al. [25] has confirmed older age as a 
key independent predictor for sub-optimal immunologic 
response as thymus activity decreases with age [26]. This 
finding agreed with our result where older age was sta-
tistically significant negative predictor of CD4+ gain on 
multiple regression.
The pre-treatment CD4+  count in relation to sub-
optimal immunologic response, however, is controversial 
as some literatures favour higher baseline CD4+  (>200 
cells/mm3) [26] and explained it as “starting treatment 
at higher CD4+  cell counts limits the scope for further 
increases”. Other literatures favoured lower baseline 
CD4+  count (<200  cells/mm3) and this is biologically 
plausible given that a low nadir pre-treatment CD4+ cell 
count is thought to be suggestive of more extensive 
depletion of CD4+  cells in the gut-associated lymphoid 
tissue during acute HIV infection, and may be delayed or 
refractory to reconstitution with ART [27].
As this study has short comings including absence of 
viral marker measurement to conclude the rate of sub-
optimal immunologic recovery among the patients, further 
study with quality design is needed as lack of knowledge 
about this subgroup may contribute to inadequate clinical 
management and current HIV treatment guidelines do not 
provide specific applicable guidance [18].
The overall random effect linear regression analy-
sis had pointed out that, baseline BMI, sex, age, base-
line CD4+  count, and exposure to TDF based regimen 
were independent predictors for CD4+  change over 
time. The marginal effects of each regimens con-
firmed that the immunologic outcome associated with 
TDF based EFV preparations was more convincing 
and made it the golden regimen to be utilized in this 
Table 4 The predicted mean CD4+  change of  patients treated with  AZT and TDF based regimens at  JUSH, September 
2012 to July 2014
Status Status Delta‑method t [95% CI] P value
Margins Standard error
Unexposed AZT3TC/NVP 319.11 19.34 16.50 281.02,357.20 P < 0.001
AZT/3TC/EFV 281.54 18.39 15.31 245.31,317.77 P < 0.001
Exposed TDF/3TC/NVP 295.73 18.39 16.08 259.50,331.96 P < 0.001
TDF/3TC/EFV 347.65 18.39 18.90 311.42,383.89 P < 0.001
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setup (margins  =  347.65  cells/mm3/, P  <  0.001) fol-
lowed by AZT/3TC/NVP (m  =  319.11  cells/mm3, 
P  <  0.001)and TDF/3TC/NVP (m =  295.73, P  <  0.001). 
However, AZT/3TC/EFV had lowest predicted change in 
CD4+  count (m =  281.54, P < 0.001). This implies that 
this regimen has minimal immunologic response and its 
clinical utilization need to be reconsidered.
Females had greater CD4+  improvement over time. 
Accordingly, every visit of female patients was associated 
with the average CD4+ count of 39 cells/mm3 (β = 33.86 
[33.11, 43.24], P = 0.013). Similar study from Lao Dem-
ocratic Republic strengthen this finding [28]. But it was 
inconsistent with study from Asia [19] probably due to 
differences in study setup and sample size (1676 versus 
280), where females contribute only 26% of the sample 
analysed.
The impact of age on immunologic recovery was well 
described [26] and this study had found concordance 
with previous findings. Accordingly, the CD4+  gain 
attained by younger (<25  years) patients was +66 cells/
mm3 as compared to those older than 45  years of age 
(β = −66.19, 95% CI [−126.68,−5.70], P =  0.032). The 
finding is consistent with the studies from Asia [19] and 
Ghana [29] and which reported the inverse relationship 
between age and CD4+ gain. This is mainly due to failure 
of cellular expansion or non-sustained cell survival in the 
periphery or age related central degeneration of thymus 
function as patients become older [18].
In the cohort, those with BMI ≥ 18.5 kg/m2 had a bet-
ter immunologic outcome and each visit was associated 
with 32 cells/mm3 of CD4+  count advantage as com-
pared to patients with BMI  <  18.5  kg/m2 (β  =  −32.22, 
95% CI [17.23,51.85], P < 0.001). This is concurrent with 
the study by Bastard et al. [ [28].] in which BMI > 18 kg/
m2 was reported to have a protective effect for CD4 
count increment at 9 months of therapy (HR = 0.39, 95% 
CI 0.25–0.60). This implies that higher BMI is a sign of 
good nutritional status and it is fertile ground for better 
immunologic revival.
The baseline CD4+  count was another positive pre-
dictor for successful immunologic revival. So, a patient 
has a 0.879 CD4+  cell count advantage over time, for 
every count higher in initial CD4+  count, when com-
pared to his/her counterpart (B = 0.879 95% CI [0.70, 
1.06], P < 0.001). This finding is consistent form study 
by Lawrence et  al. [27] and Mustapha et  al. [29] in 
which higher baseline CD4+ count was associated with 
good immunologic outcome. This might be due to less 
extensively depleted immune system will be boosted 
easily after initiation of ART. The overall clinical and 
immunological findings were suggestive of better out-
come of ART if initiated at higher CD4+  count. This 
finding also agrees with the recent WHO ART guide-
lines [30] which described the initiation of ART irre-
spective of WHO stage and CD4+ count in adolescents 
and adults.
In contrary, the finding disagrees with some studies 
showing poor immunologic recovery including discord-
ant responders when ART was commenced at higher 
CD4+ count [31]. This may be due to the goal CD4+ in 
HIV patients (500 cells/mm3) [32] can be attained imme-
diately in those with higher baseline CD4+  and further 
increment could be impossible. The reason for the devia-
tion might be due to differences in sample size and set-
up. The multicenterity of the previous study might also 
contribute for the difference.
From this study, patients randomized to TDF group 
had a significant CD4+ count advantage per visit relative 
to patients randomized to AZT group (B =+34.08, 95% 
CI [7.80, 60.35], P = 0.001). This study is consistent with 
most of the previous findings that described TDF based 
regimens with better immunologic outcome [9, 14, 31, 
32].
Conclusions
The results of this study suggest that TDF based regi-
mens especially, TDF/3TC/EFV had excellent immuno-
logic recovery followed by AZT based NVP. Since aged 
patients, those with baseline CD4+  count  <200 cells/
mm3 and patients with pre-treatment BMI  <  18.5 were 
poor immunologic responders, they need special atten-
tion while delivering care and treatment. However, the 
prevalence of sub-immunologic recovery among the TDF 
users in the resource constrained settings needs to be 
assessed further.
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